A world leader in the field of in vitro diagnostics for 50 years, bioMérieux is present in more than 150 countries through 42 subsidiaries and a large network of distributors. In 2014, revenues reached €1.698 billion with 88% of sales outside of France. bioMérieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products. bioMérieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479). Other information can be found at www.biomerieux.com
In 2013, bioMerieux celebrated a major milestone, our 50th anniversary. Our development during these years has been driven by a pioneering spirit and unrelenting commitment to improve public health worldwide. Today, in more than 150 countries through 42 subsidiaries and a large network of distributors, bioMerieux provides diagnostic solutions that improve patient health and consumer safety.
We develop tests that bring high medical value for clinical decisiopns in the areas of infectious diseases, cardiovascular emergencies and targeted cancers. In industrial applications, we contribute to preventing contamination risks in agri-food, pharmaceutical and cosmetic products.
We also bring progress to laboratories: by increasing automation and improving data management, we are helping to reinforce the efficiency of healthcare structures, increase lab productivity, and reduce healthcare costs.
bioMérieux is determined to continue to play a pioneering role by innovating and designing the diagnostics of the future to address the major challenges for public health worldwide.